<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="101">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01220492</url>
  </required_header>
  <id_info>
    <org_study_id>beijing302-002</org_study_id>
    <nct_id>NCT01220492</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis</brief_title>
  <official_title>Phase 1/2 Study of UC-MSC Treatment for the Evaluation the Efficacy and Safety in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized
      by distortion of the hepatic architecture and formation of regenerative nodules. The liver
      transplantation is one of the only effective therapies available to such patients. However,
      lack of donors, surgical complications, rejection, and high cost are it`s serious problems.
      The potential for stem cells to differentiate into hepatocytes cells was recently confirmed.
      Particularly, autologous bone marrow-derived mesenchymal stem cell (BM-MSC) has been
      demonstrated to decrease MELD score and increase serum albumin in 4 of patients with
      decompensated liver cirrhosis. Therefore, the investigators propose a hypothesis that
      umbilical cord-derived MSCs (UC-MSC) can also improve the disease conditions of LC patients,
      particularly reducing the decompensated conditions in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized
      by distortion of the hepatic architecture and formation of regenerative nodules. The liver
      transplantation is one of the only effective therapies available to such patients. However,
      lack of donors, surgical complications, rejection, and high cost are it`s serious problems.

      The potential for stem cells to differentiate into hepatocytes cells was recently confirmed.
      In particular, bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has been
      applicated in the clinic for treat several human diseases such as GVHD, cardiac injury and
      brain injury, and displayed good tolerance and efficiency. BM-MSC has also been used to
      treat human liver diseases such as liver failure and liver cirrhosis. In a phase 1 study,
      autologous BM-MSC transplantation has potential to decrease MELD score and increase serum
      albumin in 4 of patients with decompensated liver cirrhosis.

      The purpose of this study is to learn whether and how umbilical cord-derived MSCs (UC-MSC)
      can improve the disease conditions in patients with liver cirrhosis. This study will also
      look at how well BM-MSC is tolerated and its safety in LC patients.

      Participants in the study will be randomly assigned to one of two treatment arms:

      Arm A: Participants will receive 8 weeks of conserved treatment plus UC-MSC treatment.

      Arm B: Participants will receive 8 weeks of conserved treatment plus saline.

      UC-MSC will be prepared according to standard procedures and is collected in plastic bags
      containing anti coagulant. MSCs are given via i.v. under sonography monitoring. After cell
      therapy, patients are followed up at week 4, 8, 12, 24, 36 and 48. The evaluation of some
      clinical parameters such as the level of ascites volume and ascites disappearance rate,
      serum alanine aminotransferase (ALT), total bilirubin (TB),prothrombin time (PT), albumin
      (ALB), prealbumin(PA), the rountin blood test, renal function test are detected at these
      timepoints. MELD-Na scores and clinical symptoms as well as complication were also observed
      simultaneously.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>ascites volume</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the patient number of liver function worsening</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of patients with ascites after 12-week treatment</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The levels of serum alanine aminotransferase</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The levels of serum total bilirubin</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The levels of INR</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The levels of serum prothrombin activity</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function evaluation using MELD-Na score model</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma albumin level</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma HBV load</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood routine examination</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function tests</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>conventional plus MSC treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the week 48 study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional plus placebo treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the week 48 study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional plus MSC treatment</intervention_name>
    <description>received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 8 weeks.</description>
    <arm_group_label>conventional plus MSC treatment</arm_group_label>
    <other_name>conventional plus MSC treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional plus placebo treatment</intervention_name>
    <description>received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.</description>
    <arm_group_label>conventional plus placebo treatment</arm_group_label>
    <other_name>conventional plus placebo treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Liver cirrhosis

          2. Negative pregnancy test (female patients in fertile age)

          3. written consent

        Exclusion Criteria:

          1. Hepatocellular carcinoma or other malignancies

          2. Pregnancy

          3. sepsis

          4. Presence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.)

          5. Cardiac, renal or respiratory failure

          6. Active thrombosis of the portal or hepatic veins
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Sheng Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing 302 Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fu-Sheng Wang, Professor</last_name>
    <phone>86-10-63879735</phone>
    <phone_ext>2015.12</phone_ext>
    <email>fswang@bbn.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Zhang, Doctor</last_name>
      <phone>86-10-63879735</phone>
      <phone_ext>2015.12</phone_ext>
      <email>zhangzheng1975@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Fu-Sheng Wang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar 8;371(9615):838-51. Review.</citation>
    <PMID>18328931</PMID>
  </reference>
  <reference>
    <citation>Kisseleva T, Gigante E, Brenner DA. Recent advances in liver stem cell therapy. Curr Opin Gastroenterol. 2010 Jul;26(4):395-402.</citation>
    <PMID>20495456</PMID>
  </reference>
  <reference>
    <citation>Kharaziha P, Hellstr√∂m PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1199-205.</citation>
    <PMID>19455046</PMID>
  </reference>
  <results_reference>
    <citation>Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, Baharvand H, Ghavamzadeh A, Malekzadeh R. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007 Oct;10(4):459-66. Erratum in: Arch Iran Med. 2008 Jan;11(1):135.</citation>
    <PMID>17903050</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 10, 2011</lastchanged_date>
  <firstreceived_date>October 4, 2010</firstreceived_date>
  <responsible_party>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>ascites</keyword>
  <keyword>serum albumin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
</clinical_study>
